الفهرس 
Chronic Kidney DiseaseOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Abstract
Context: Neuropeptide Y (NPY) is a sympathetic neurotransmitter with wide-ranging effects in various organ systems, from the central nervous system (CNS) to the cardiovascular (CV) system, the bone and the renal system. There is a strong association between serum concentration of NpY and deterioration of eGFR and proteinuria as suggested by recent studies 1,2, however, its real effect on chronic kidney disease (CKD) progression is uncertain.
Aim:
Assess the relationship between NpY and progression of CKD.
Settings and Design:
An observational, prospective case-control study of thirty CKD adult patients and thirty healthy control adult subjects.
Methods and Material:
All participants were conducted to renal function tests (serum creatinin, blood urea, serum Na, K, P and Ca and calculation of estimated glomerular filtration rate), complete blood count, urinary protein/creatinin ratio, serum NpY and pelvi-abdominal ultrasonography at baseline and repeated for the patients only after six months as follow up.
Statistical analysis used:
Statistical presentation and analysis of the present study was conducted, using the mean, standard deviation, student t-test, Paired t-test, Chi-square, Linear Correlation Coefficient and Analysis of variance [ANOVA] tests by SPSS V17.
Results:
The mean of serum NpY was 438.333 ± 206.850 at baseline then became 630.667 ± 264.926 after follow up. Urinary PCR ranged from 0.2- 3.1 at baseline to 0.2- 2 after six months. The patients’ group mean eGFR was 36.900±17.851 and became 31.373±17.852 ml/min/1.73m².
Conclusion:
Serum NpY could be a useful marker that can be used as diagnostic and progression predictor for CKD.